Arrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on Tuesday

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) is scheduled to be releasing its earnings data after the market closes on Tuesday, November 26th. Analysts expect Arrowhead Pharmaceuticals to post earnings of ($0.63) per share for the quarter. Parties that wish to listen to the company's conference call can do so using this link.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR traded down $0.42 during trading hours on Tuesday, reaching $18.60. The stock had a trading volume of 997,736 shares, compared to its average volume of 1,201,221. Arrowhead Pharmaceuticals has a 12-month low of $17.05 and a 12-month high of $39.83. The stock has a 50 day simple moving average of $20.00 and a 200 day simple moving average of $23.35. The stock has a market cap of $2.31 billion, a P/E ratio of -3.98 and a beta of 0.93.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ARWR shares. Piper Sandler reiterated an "overweight" rating and issued a $62.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, October 8th. StockNews.com raised shares of Arrowhead Pharmaceuticals to a "sell" rating in a report on Tuesday, November 12th. HC Wainwright reiterated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Friday, October 11th. B. Riley reissued a "buy" rating and set a $55.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, August 12th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arrowhead Pharmaceuticals in a report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $45.33.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.